BABA vs PHM

The Advanced Deterministic Scorecard reveals a mixed financial profile for Alibaba (BABA), with a weak Piotroski F-Score of 4/9 indicating suboptimal financial health, and no available Altman Z-Score limiting distress risk assessment. While valuation metrics appear favorable relative to peers—especially a Price/Sales of 0.41 and Forward P/E of 19.50—earnings growth is sharply negative (YoY EPS down 71%), and recent quarterly beats have reversed into consistent misses over the last four quarters. Strong insider sentiment and a bullish analyst consensus (strong_buy) contrast with deteriorating profitability and weak technical trends (10/100). The stock trades significantly above the Graham Number ($102.68) and intrinsic value estimate ($51.38), suggesting overvaluation unless growth rebounds materially.

PHM exhibits a contradictory profile: a weak Piotroski F-Score of 3/9 indicates deteriorating operational health, yet the balance sheet remains exceptionally clean with a Debt/Equity ratio of 0.19. While the current price of $119.21 sits below the Graham Number ($125.69), it is significantly higher than the growth-based intrinsic value of $72.38, reflecting a premium that is not supported by current negative growth trends. Revenue and earnings are in a sharp cyclical decline (-12.4% and -30.4% YoY respectively), driven by mortgage rate volatility and affordability challenges. The stock is currently a battle between strong solvency and weakening fundamentals.